Your browser doesn't support javascript.
loading
The beneficial metabolic actions of prolactin.
Macotela, Yazmín; Ruiz-Herrera, Xarubet; Vázquez-Carrillo, Dina I; Ramírez-Hernandez, Gabriela; Martínez de la Escalera, Gonzalo; Clapp, Carmen.
Afiliação
  • Macotela Y; Instituto de Neurobiología, Universidad Nacional Autónoma de México (UNAM), Querétaro, Mexico.
  • Ruiz-Herrera X; Instituto de Neurobiología, Universidad Nacional Autónoma de México (UNAM), Querétaro, Mexico.
  • Vázquez-Carrillo DI; Instituto de Neurobiología, Universidad Nacional Autónoma de México (UNAM), Querétaro, Mexico.
  • Ramírez-Hernandez G; Instituto de Neurobiología, Universidad Nacional Autónoma de México (UNAM), Querétaro, Mexico.
  • Martínez de la Escalera G; Instituto de Neurobiología, Universidad Nacional Autónoma de México (UNAM), Querétaro, Mexico.
  • Clapp C; Instituto de Neurobiología, Universidad Nacional Autónoma de México (UNAM), Querétaro, Mexico.
Front Endocrinol (Lausanne) ; 13: 1001703, 2022.
Article em En | MEDLINE | ID: mdl-36213259
The role of prolactin (PRL) favoring metabolic homeostasis is supported by multiple preclinical and clinical studies. PRL levels are key to explaining the direction of its actions. In contrast with the negative outcomes associated with very high (>100 µg/L) and very low (<7 µg/L) PRL levels, moderately high PRL levels, both within but also above the classically considered physiological range are beneficial for metabolism and have been defined as HomeoFIT-PRL. In animal models, HomeoFIT-PRL levels counteract insulin resistance, glucose intolerance, adipose tissue hypertrophy and fatty liver; and in humans associate with reduced prevalence of insulin resistance, fatty liver, glucose intolerance, metabolic syndrome, reduced adipocyte hypertrophy, and protection from type 2 diabetes development. The beneficial actions of PRL can be explained by its positive effects on main metabolic organs including the pancreas, liver, adipose tissue, and hypothalamus. Here, we briefly review work supporting PRL as a promoter of metabolic homeostasis in rodents and humans, the PRL levels associated with metabolic protection, and the proposed mechanisms involved. Finally, we discuss the possibility of using drugs elevating PRL for the treatment of metabolic diseases.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Resistência à Insulina / Intolerância à Glucose / Diabetes Mellitus Tipo 2 / Fígado Gorduroso Tipo de estudo: Risk_factors_studies Limite: Animals / Humans Idioma: En Revista: Front Endocrinol (Lausanne) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: México País de publicação: Suíça

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Resistência à Insulina / Intolerância à Glucose / Diabetes Mellitus Tipo 2 / Fígado Gorduroso Tipo de estudo: Risk_factors_studies Limite: Animals / Humans Idioma: En Revista: Front Endocrinol (Lausanne) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: México País de publicação: Suíça